STI Testing in Men
At-Home vs Clinic Panels, the Asymptomatic-Carriage Problem, and the Telehealth STI-Testing Market
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- NAAT and serologic assays FDA-cleared; CDC screening guidance applies
Reference only. Not medical advice.
What can go wrong
The practical risks are false reassurance and gaps in linkage to care. A urine-only panel can return reassuringly negative while a rectal or pharyngeal infection goes undetected; an early-window HIV or syphilis test can miss recent infection. Self-collection errors can reduce sensitivity. Direct-to-consumer marketing may imply more comprehensive coverage than a given panel provides, and a positive result without a clear treatment and partner-notification pathway has limited value. Over-testing for organisms of uncertain significance (e.g., Ureaplasma) can also drive unnecessary antibiotics.
This is something to take to a clinician. The Atlas can tell you what is known about sti testing in men in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
STI testing in men spans urine and swab nucleic acid amplification tests (NAATs) for chlamydia, gonorrhea, and trichomonas; blood tests for HIV and syphilis; and serology or PCR for herpes and hepatitis where indicated. The central clinical challenge is asymptomatic carriage: because a large share of male chlamydial and gonococcal infection causes no symptoms, symptom-triggered testing alone misses many infections, and extragenital (rectal, pharyngeal) sites are missed by urine-only testing. The CDC recommends at least annual screening of sexually active MSM at all exposed sites, with more frequent testing for higher risk and routine HIV screening. A large direct-to-consumer market (LetsGetChecked, Everlywell, and men's-health telehealth platforms) sells at-home collection kits, which improve access but vary in what they cover and how results are confirmed and treated.
What the panels actually cover, what they miss, and why testing avoidance is its own epidemic.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
NAATs amplify pathogen-specific nucleic acid and are the most sensitive tests for chlamydia, gonorrhea, and trichomonas; first-catch urine is suitable for urethral infection, while rectal and pharyngeal swabs are needed to detect extragenital infection that urine misses. HIV testing uses fourth-generation antigen/antibody assays (which shorten the window period) with confirmatory testing; syphilis uses treponemal and non-treponemal serology. At-home kits provide collection materials and mail samples to certified labs; the analytic test is generally the same NAAT or serology used in clinics, so the main differences are in self-collection adequacy, breadth of panel, confirmation, and linkage to treatment.
The asymptomatic-carriage problem and the limits of at-home kits
Symptom-based testing systematically under-detects infection because so much male infection is silent, and because extragenital infections are common in MSM but absent on urine testing. Comprehensive screening therefore samples all exposed sites. At-home kits expand access and reduce stigma-related avoidance, but limitations matter: some panels omit extragenital swabs, omit M. genitalium or trichomonas, have window-period blind spots, and depend on the user to follow up reactive results with confirmation and treatment. A negative at-home HIV or syphilis test taken too soon after exposure can falsely reassure. Quality services pair testing with clinician review and treatment pathways.
What people get wrong
Often saidA clear urine STI test means you are STI-free
ActuallyUrine NAAT does not detect rectal or pharyngeal infection, nor HIV or syphilis; comprehensive screening requires site-specific and blood tests.
Often saidAt-home kits cover everything a clinic does
ActuallyPanels vary; some omit extragenital swabs, M. genitalium, or have window-period limits, and value depends on confirmation and treatment linkage.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- NAAT targets
- Chlamydia, gonorrhea, trichomonas (and M. genitalium where added)
- Blood tests
- HIV, syphilis (and hepatitis where indicated)
- Key gap
- Urine-only testing misses rectal/pharyngeal infection
- MSM screening
- At least annual, all exposed sites (CDC)
- At-home brands
- LetsGetChecked, Everlywell, telehealth platforms
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about STI Testing in Men. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
CDC STI Treatment Guidelines2021
Defined site-specific NAAT screening, including extragenital testing for MSM, and screening intervals
Studies on self-collected extragenital NAAT performance2010s
Self-collected rectal and pharyngeal swabs perform comparably to clinician-collected for NAAT
Evaluations of direct-to-consumer STI testing2010s-2020s
Showed improved access and uptake but variable panel breadth and linkage-to-care